TP53 and breast carcinoma: Although lower levels of Beclin-1 expression may contribute to the pathogenesis or progression of HER2-enriched basal-like breast cancers with TP53 mutations [47], our current report represents the first study to show a negative correlation of Beclin-1 with EHMT2, which is associated with a poor prognosis in breast cancers.